Report on a new subcutaneous starting-dose option for an anti-amyloid Alzheimer's therapy and its planned late-summer rollout.
Key Takeaways
- FDA approved a once-weekly subcutaneous starting dose of lecanemab for early Alzheimer's treatment
- Sub-studies from the Clarity AD long-term extension showed equivalent exposure to IV dosing
- Patients may now start and continue therapy by subcutaneous injection with flexible administration options